Stockwatch: The Best Of Earnings And The Worse Of Earnings
This article was originally published in Scrip
Last week, approaching the end of this third-quarter earnings season, it seemed that all the good and all the bad events that investors could expect happened in the same week. On the positive side, the acquisitions of the biotechnology companies Dyax Corp. and ZS Pharma, Inc. were announced, Lexicon Pharmaceuticals, Inc. licensed its Phase III-ready product to Sanofi, and the NASDAQ Biotchnology Index (NBI) finished the week just into positive territory after a gut-wrenching down-day on Thursday.
Register for our free email digests: